Notice of Allowance from ARIPO

RNS Number : 0372Q

Eden Research plc

09 October 2013

 



Eden Research Plc

("Eden" or "Company")

Notice of Allowance from ARIPO for Yeast Glucan Particles

Eden Research plc (AIM: EDEN), the AIM listed natural micro-encapsulation company, announces that the African Regional Intellectual Property Organisation (ARIPO) has issued a Notice of Allowance for Patent (Application No. AP/P/2006/003845) for Yeast Glucan Particles.

The patent relates to the use of yeast glucan particles as a natural carrier particle for a terpene or combination of terpenes, with or without an additional active substance.

The ARIPO designated states for this application are the following: Botswana, Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Sudan, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe.

This notice of allowance follows on from the Grant of Patent received earlier in the year from ARIPO for Eden's Plant Bacteria Fungi Formulae, which covers the formulation of more than one terpene selected from a group of four terpenes.

Clive Newitt, Managing Director of Eden comments: "We are delighted to receive a further Notice of Allowance from ARIPO which further strengthens our intellectual property portfolio in Africa.

"Africa has become an increasingly significant market in the worldwide food and crop production sector with a growing amount of the food and other crops (such as cut flowers) being exported to European supermarkets. The increased patent coverage in the ARIPO region ensures that Eden licensees can commercialise products with strong IP protection surrounding the use of Eden's unique technologies."

Enquiries:

Eden Research plc	www.edenresearch.com
Clive Newitt, Managing Director	Tel: [phone]
Alex Abrey, Chief Financial Officer
W H Ireland Limited	Tel: [phone]
John Wakefield
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus (Media Relations)	Mob: [phone]
Paul Cornelius (Investor Relations)	Mob: [phone]

Notes:

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit www.edenresearch.com 

 

END

 

 

MSCDMMGGKRFGFZM